These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35263841)

  • 1. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
    Sun S; Ko YH; Jin JY; Woo IS; Park SY; Eom YA; Kang JH; Kim HK
    Korean J Intern Med; 2023 May; 38(3):406-416. PubMed ID: 35263841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
    Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
    Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
    Boccia RV; Gordan LN; Clark G; Howell JD; Grunberg SM;
    Support Care Cancer; 2011 Oct; 19(10):1609-17. PubMed ID: 20835873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
    Armbruster SD; Fellman BM; Jhingran A; Eifel PJ; Klopp AH; Coleman RL; Ramondetta LM; Frumovitz M
    Support Care Cancer; 2021 Jan; 29(1):213-222. PubMed ID: 32338316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
    Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G
    Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
    Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
    Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
    Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
    Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
    Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
    Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
    Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.